$2.46 Billion is the total value of Tekla Capital Management LLC's 194 reported holdings in Q1 2019. The portfolio turnover from Q4 2018 to Q1 2019 was 25.5% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| CELG | Buy | Celgene Corporation | $139,030,000 | +57.0% | 1,473,710 | +6.6% | 5.65% | +48.9% |
| AMGN | Buy | Amgen Inc. | $133,819,000 | +1.4% | 704,383 | +3.9% | 5.44% | -3.8% |
| PFE | Buy | Pfizer Inc. | $87,945,000 | +32.8% | 2,070,765 | +36.5% | 3.57% | +26.0% |
| MRK | Buy | Merck & Co., Inc. | $82,595,000 | +46.4% | 993,083 | +34.5% | 3.35% | +38.9% |
| VRTX | Buy | Vertex Pharmaceuticals Incorporated | $81,621,000 | +15.6% | 443,712 | +4.1% | 3.32% | +9.7% |
| REGN | Buy | Regeneron Pharmaceuticals, Inc. | $58,116,000 | +14.1% | 141,532 | +3.7% | 2.36% | +8.2% |
| MDT | Buy | Medtronic plcshares | $44,812,000 | +2.3% | 492,002 | +2.2% | 1.82% | -2.9% |
| ANTM | Buy | Anthem, Inc. | $40,567,000 | +9.4% | 141,358 | +0.1% | 1.65% | +3.8% |
| LLY | Buy | Eli Lilly and Company | $38,321,000 | +53.0% | 295,320 | +36.4% | 1.56% | +45.1% |
| ABT | Buy | Abbott Laboratories | $36,536,000 | +29.0% | 457,048 | +16.7% | 1.48% | +22.3% |
| BMY | Buy | Bristol-Myers Squibb Company | $35,212,000 | +3.7% | 738,044 | +13.0% | 1.43% | -1.6% |
| CVS | Buy | CVS Health Corporation | $27,308,000 | -9.5% | 506,364 | +9.9% | 1.11% | -14.2% |
| ZTS | Buy | Zoetis Inc.class a | $25,872,000 | +20.3% | 257,001 | +2.2% | 1.05% | +14.1% |
| ISRG | Buy | Intuitive Surgical, Inc. | $22,984,000 | +22.3% | 40,281 | +2.7% | 0.93% | +16.0% |
| SGEN | Buy | Seattle Genetics, Inc. | $21,234,000 | +65.6% | 289,925 | +28.1% | 0.86% | +57.0% |
| BMRN | Buy | BioMarin Pharmaceutical Inc. | $19,728,000 | +11.7% | 222,086 | +7.1% | 0.80% | +6.0% |
| NBIX | Buy | Neurocrine Biosciences, Inc. | $19,530,000 | +26.4% | 221,678 | +2.5% | 0.79% | +20.0% |
| CI | Buy | Cigna Corporation | $18,777,000 | +54.3% | 116,756 | +82.2% | 0.76% | +46.4% |
| WELL | Buy | Welltower Inc. | $18,416,000 | +482.4% | 237,322 | +420.9% | 0.75% | +454.1% |
| BSX | Buy | Boston Scientific Corporation | $18,177,000 | +15.6% | 473,619 | +6.4% | 0.74% | +9.7% |
| EXEL | Buy | Exelixis, Inc. | $16,148,000 | +141.8% | 678,467 | +99.9% | 0.66% | +129.4% |
| PRAH | Buy | PRA Health Sciences, Inc. | $15,831,000 | +144.3% | 143,537 | +103.7% | 0.64% | +132.1% |
| IDXX | Buy | IDEXX Laboratories, Inc. | $14,233,000 | +48.4% | 63,654 | +23.4% | 0.58% | +40.6% |
| BGNE | Buy | BeiGene, Ltd.sponsored adr | $12,525,000 | +4.1% | 94,889 | +10.7% | 0.51% | -1.2% |
| ALNY | Buy | Alnylam Pharmaceuticals, Inc. | $12,472,000 | +35.6% | 133,458 | +5.8% | 0.51% | +28.7% |
| HCA | Buy | HCA Healthcare, Inc. | $11,678,000 | +26.2% | 89,569 | +20.5% | 0.47% | +19.7% |
| NKTR | Buy | Nektar Therapeutics | $9,532,000 | +207.3% | 283,679 | +200.6% | 0.39% | +191.0% |
| IONS | Buy | Ionis Pharmaceuticals, Inc. | $8,906,000 | +98.9% | 109,720 | +32.5% | 0.36% | +88.5% |
| XLRN | Buy | Acceleron Pharma Inc. | $8,773,000 | +18.0% | 188,388 | +10.3% | 0.36% | +11.9% |
| XRAY | Buy | DENTSPLY SIRONA Inc. | $7,762,000 | +66.0% | 156,521 | +24.6% | 0.32% | +57.5% |
| ESPR | Buy | Esperion Therapeutics, Inc. | $7,412,000 | +13.2% | 184,607 | +29.7% | 0.30% | +7.5% |
| STRO | Buy | Sutro Biopharma, Inc. | $7,304,000 | +252.2% | 641,268 | +178.9% | 0.30% | +233.7% |
| ALKS | Buy | Alkermes plcshares | $7,227,000 | +61.9% | 198,048 | +30.9% | 0.29% | +53.9% |
| ASND | Buy | Ascendis Pharma A/Ssponsored adr | $7,222,000 | +171.9% | 61,360 | +44.7% | 0.29% | +157.0% |
| RMD | Buy | ResMed Inc. | $7,171,000 | +7.4% | 68,974 | +17.6% | 0.29% | +1.7% |
| LH | Buy | Laboratory Corporation of America Holdingssponsored adr | $6,985,000 | +90.0% | 45,657 | +56.9% | 0.28% | +80.9% |
| ABMD | Buy | ABIOMED, Inc. | $6,850,000 | +70.7% | 23,986 | +94.2% | 0.28% | +61.6% |
| ICPT | Buy | Intercept Pharmaceuticals, Inc. | $6,631,000 | +393.0% | 59,275 | +344.1% | 0.27% | +363.8% |
| AGIO | Buy | Agios Pharmaceuticals, Inc. | $6,189,000 | +173.7% | 91,776 | +87.2% | 0.25% | +158.8% |
| STE | New | STERIS plcshares | $6,146,000 | – | 48,003 | +100.0% | 0.25% | – |
| WCG | Buy | WellCare Health Plans, Inc. | $5,202,000 | +69.5% | 19,286 | +48.4% | 0.21% | +61.1% |
| TECH | New | Bio-Techne Corporation | $4,309,000 | – | 21,701 | +100.0% | 0.18% | – |
| LGND | Buy | Ligand Pharmaceuticals, Inc. | $3,758,000 | +4.7% | 29,895 | +13.0% | 0.15% | -0.6% |
| TAK | New | Takeda Pharmaceutical Company Limitedsponsored ads | $3,628,000 | – | 178,128 | +100.0% | 0.15% | – |
| ARGX | New | argenx SEsponsored adr | $3,543,000 | – | 28,381 | +100.0% | 0.14% | – |
| AERI | Buy | Aerie Pharmaceuticals, Inc. | $3,254,000 | +132.4% | 68,496 | +76.7% | 0.13% | +120.0% |
| NVCR | Buy | Novocure Limitedordinary shares | $3,177,000 | +287.4% | 65,964 | +169.2% | 0.13% | +268.6% |
| ACAD | New | ACADIA Pharmaceuticals Inc. | $2,812,000 | – | 104,714 | +100.0% | 0.11% | – |
| XNCR | Buy | Xencor, Inc. | $2,248,000 | +10.7% | 72,382 | +28.9% | 0.09% | +4.6% |
| GHDX | Buy | Genomic Health, Inc. | $1,858,000 | +66.0% | 26,531 | +52.7% | 0.08% | +56.2% |
| MDGL | Buy | Madrigal Pharmaceuticals, Inc. | $1,671,000 | +122.2% | 13,340 | +100.0% | 0.07% | +112.5% |
| SYNH | New | Syneos Health, Inc.class a | $1,502,000 | – | 29,027 | +100.0% | 0.06% | – |
| WVE | New | WaVe Life Sciences Ltd.shares | $1,179,000 | – | 30,336 | +100.0% | 0.05% | – |
| VKTX | Buy | Viking Therapeutics, Inc. | $1,133,000 | +159.9% | 114,016 | +100.0% | 0.05% | +142.1% |
| ALLK | New | Allakos Inc. | $989,000 | – | 24,414 | +100.0% | 0.04% | – |
| MYGN | New | Myriad Genetics, Inc. | $682,000 | – | 20,549 | +100.0% | 0.03% | – |
| HZNP | New | Horizon Pharma plcshares | $511,000 | – | 19,350 | +100.0% | 0.02% | – |
| DNLI | New | Denali Therapeutics Inc. | $450,000 | – | 19,372 | +100.0% | 0.02% | – |
| CLDX | New | Celldex Therapeutics, Inc. | $35,000 | – | 7,053 | +100.0% | 0.00% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2019-05-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| Gilead Sciences, Inc. | 41 | Q2 2023 | 12.4% |
| Amgen, Inc. | 41 | Q2 2023 | 5.8% |
| Biogen Inc. | 41 | Q2 2023 | 6.5% |
| Vertex Pharmaceuticals Incorporated | 41 | Q2 2023 | 5.3% |
| Regeneron Pharmaceuticals, Inc. | 41 | Q2 2023 | 9.1% |
| Illumina, Inc. | 41 | Q2 2023 | 3.4% |
| BioMarin Pharmaceutical Inc. | 41 | Q2 2023 | 2.9% |
| Teva Pharmaceutical Industries Ltd. | 41 | Q2 2023 | 3.2% |
| Neurocrine Biosciences, Inc. | 41 | Q2 2023 | 1.4% |
| McKesson Corporation | 41 | Q2 2023 | 2.2% |
View Tekla Capital Management LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Rallybio Corp | January 23, 2023 | 1,727,067 | 4.6% |
| Zyla Life SciencesSold out | January 29, 2021 | 0 | 0.0% |
| ARCA biopharma, Inc. | January 24, 2020 | 36,068 | 2.3% |
| Verona Pharma plc | February 12, 2019 | 5,296,845 | 4.9% |
| Alliqua BioMedical, Inc. | February 12, 2018 | 165,000 | 3.3% |
| PIERIS PHARMACEUTICALS, INC. | February 12, 2018 | 1,962,380 | 4.4% |
| Intellipharmaceutics International Inc. | February 13, 2015 | 2,184,000 | 9.0% |
| HERON THERAPEUTICS, INC. /DE/ | February 14, 2014 | 20,598,613 | 4.2% |
| MEDWAVE INC | February 14, 2012 | 1,277,372 | 9.8% |
| MZT Holdings, Inc. | February 14, 2012 | 2,553,420 | 4.0% |
View Tekla Capital Management LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2023-08-10 |
| 13F-HR | 2023-05-10 |
| 13F-HR | 2023-02-10 |
| SC 13G/A | 2023-01-23 |
| 13F-HR | 2022-11-01 |
| 13F-HR | 2022-07-29 |
| 13F-HR | 2022-05-13 |
| 13F-HR | 2022-02-14 |
| SC 13G | 2022-01-21 |
| 13F-HR | 2021-11-12 |
View Tekla Capital Management LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.